No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
The E2810 research study was conducted to determine whether taking the oral drug pazopanib (Votrient) following surgery to remove further metastases in patients with advanced renal cell carcinoma would improve their disease-free ...
Jun 3, 2019
0
2